In spring of 2018, we hosted a symposium at the European Renal Association – European Dialysis and Transplant Association (ERA‐EDTA) Congress in Copenhagen, Denmark. The symposium, "Epigenetics in CKD & CVD: A potential breakthrough therapy”, highlighted the unmet need for a novel approach to reduce risk in kidney and cardiovascular disease, and demonstrated the important role for epigenetics in the underlying pathology of these diseases. Speakers included: Vincent M Brandenburg, MD – University Hospital of the RWTH Aachen, Germany; Eric Stroes, MD – Academic Medical Centre, Amsterdam, The Netherlands; Louise Nordfors, PhD – Karolinska Institute, Stockholm, Sweden and; Kamyar Kalantar‐Zadeh, MD – UC Irvine School of Medicine, Irvine, USA. These renowned experts in the field of CKD presented on topics including, “Cardiovascular disease in diabetes and CKD & residual risk ‐ The promise of epigenetics”, “Epigenetics in CKD: Rationale for BET inhibition, an emerging therapeutic mechanism in renal disease and CVD”, and “A clinical view on BET inhibition in CKD & CVD: Understanding recent data and future perspectives”.
The video presentations and symposium highlights can be accessed here.